-
Something wrong with this record ?
Effect of silymarin and its polyphenolic fraction on cholesterol absorption in rats
Sobolová L, Skottová N, Vecera R, Urbánek K.
Language English Country Great Britain
- MeSH
- Antioxidants pharmacology MeSH
- Azetidines pharmacology MeSH
- Cholesterol, Dietary pharmacokinetics MeSH
- Cholestyramine Resin pharmacology MeSH
- Phenols pharmacology MeSH
- Financing, Organized MeSH
- Flavonoids pharmacology MeSH
- Intestinal Absorption drug effects MeSH
- Liver metabolism drug effects MeSH
- Rats MeSH
- Lipoproteins, VLDL blood MeSH
- Lipoproteins metabolism MeSH
- Silymarin pharmacology MeSH
- Triglycerides pharmacology MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
This study evaluated the influence of silymarin (SM) and polyphenolic fraction (PF) of silymarin on cholesterol absorption in rats fed on high cholesterol diet (HCD). HCD induced a remarkable increase in hepatic, plasma, VLDL and LDL cholesterol, a decrease in HDL cholesterol and an elevation in triacylglycerol (TAG) levels in plasma, VLDL and in the liver. SM and PF were administered as dietary supplements (1.0%) in HCD for 18 days. Intestinal cholesterol absorption was measured by dual-isotope plasma ratio method, which calculates percent of cholesterol absorption from the ratio of two labelled cholesterol doses, one given intragastrically (14C) and one intravenously (3H). Silymarin and PF significantly reduced cholesterol absorption in rats fed on HCD and caused significant decreases in plasma and VLDL cholesterol and content of cholesterol and TAG in the liver. The level of HDL cholesterol was significantly increased after silymarin, but not after administration of PF. The levels of TAG in plasma and VLDL were not affected by either silymarin or PF. These results suggest that the inhibition of cholesterol absorption caused by silymarin and its polyphenolic fraction could be a mechanism contributing to the positive changes in plasma cholesterol lipoprotein profile and in lipid content in liver.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07520155
- 003
- CZ-PrNML
- 005
- 20111210131020.0
- 008
- 090327s2006 xxk e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Sobolová, Lucie $7 xx0140327
- 245 10
- $a Effect of silymarin and its polyphenolic fraction on cholesterol absorption in rats / $c Sobolová L, Skottová N, Vecera R, Urbánek K.
- 314 __
- $a Institute of Pharmacology, Medical Faculty, Palacký University, Hnevotínská 3, 775 15 Olomouc, Czech Republic
- 520 9_
- $a This study evaluated the influence of silymarin (SM) and polyphenolic fraction (PF) of silymarin on cholesterol absorption in rats fed on high cholesterol diet (HCD). HCD induced a remarkable increase in hepatic, plasma, VLDL and LDL cholesterol, a decrease in HDL cholesterol and an elevation in triacylglycerol (TAG) levels in plasma, VLDL and in the liver. SM and PF were administered as dietary supplements (1.0%) in HCD for 18 days. Intestinal cholesterol absorption was measured by dual-isotope plasma ratio method, which calculates percent of cholesterol absorption from the ratio of two labelled cholesterol doses, one given intragastrically (14C) and one intravenously (3H). Silymarin and PF significantly reduced cholesterol absorption in rats fed on HCD and caused significant decreases in plasma and VLDL cholesterol and content of cholesterol and TAG in the liver. The level of HDL cholesterol was significantly increased after silymarin, but not after administration of PF. The levels of TAG in plasma and VLDL were not affected by either silymarin or PF. These results suggest that the inhibition of cholesterol absorption caused by silymarin and its polyphenolic fraction could be a mechanism contributing to the positive changes in plasma cholesterol lipoprotein profile and in lipid content in liver.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antioxidancia $x farmakologie $7 D000975
- 650 _2
- $a azetidiny $x farmakologie $7 D001384
- 650 _2
- $a cholesterol dietní $x farmakokinetika $7 D002791
- 650 _2
- $a cholestyraminová pryskyřice $x farmakologie $7 D002792
- 650 _2
- $a flavonoidy $x farmakologie $7 D005419
- 650 _2
- $a intestinální absorpce $x účinky léků $7 D007408
- 650 _2
- $a lipoproteiny $x metabolismus $7 D008074
- 650 _2
- $a lipoproteiny VLDL $x krev $7 D008079
- 650 _2
- $a játra $x metabolismus $x účinky léků $7 D008099
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a fenoly $x farmakologie $7 D010636
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a silymarin $x farmakologie $7 D012838
- 650 _2
- $a triglyceridy $x farmakologie $7 D014280
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Škottová, Nina, $d 1946-2018 $7 mzk2004236741
- 700 1_
- $a Večeřa, Rostislav, $d 1965- $7 mzk2004236742
- 700 1_
- $a Urbánek, Karel, $d 1937- $7 jn20000402457
- 773 0_
- $w MED00005744 $t Pharmacological research $g Roč. 53, č. 2 (2006), s. 104-112 $x 1043-6618
- 910 __
- $a ABA008 $b x $y 9
- 990 __
- $a 20090310084605 $b ABA008
- 991 __
- $a 20090716111152 $b ABA008
- 999 __
- $a ok $b bmc $g 637959 $s 490756
- BAS __
- $a 3
- BMC __
- $a 2006 $b 53 $c 2 $d 104-112 $i 1043-6618 $m Pharmacological research $x MED00005744
- LZP __
- $a 2009-B2/ipme